POPULATION BASED STUDY OF THE PREVALENCE OF EGFR MUTATIONS IN NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Skov, Birgit G. [1 ]
Hogdall, Estrid [2 ]
Clementsen, Paul [3 ]
Krasnik, Mark [1 ]
Larsen, Klaus R. [4 ]
Sorensen, Jens B. [1 ]
Mellemgaard, Anders [5 ]
机构：
[1] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark
[2] Herlev Univ Hosp, Herlev, Denmark
[3] Gentofte Univ Hosp, Hellerup, Denmark
[4] Bispebjeg Univ Hosp, Copenhagen, Denmark
[5] Univ Copenhagen, Herlev Univ Hosp, DK-1168 Copenhagen, Denmark
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
EGFR mutations; Cytology; population based; NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.06-022
引用
收藏
页码：S1082 / S1083
页数：2
相关论文
共 50 条
  • [21] ANALYSIS OF KRAS MUTATIONS IN NON-SMALL CELL LUNG CANCER (NSCLC) BRAZILIAN PATIENTS
    Couto, Patricia G. P.
    Bastos-rodrigues, Luciana
    Sabato, Cristina
    Guieiro, Fernanda
    Vilhena, Alyne
    Amaral, Nilson F.
    De Marco, Luiz
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S735 - S736
  • [22] Micrometastases in non-small cell lung cancer (NSCLC)
    Passlick, B
    LUNG CANCER, 2001, 34 : S25 - S29
  • [23] Quantification of EGFR mutations in primary and metastatic tumors in non-small cell lung cancer
    Wei, Bing
    Yang, Ke
    Zhao, Jiuzhou
    Chang, Yuxi
    Ma, Zihui
    Dong, Bing
    Guo, Yongjun
    Ma, Jie
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2014, 33
  • [24] Quantification of EGFR mutations in primary and metastatic tumors in non-small cell lung cancer
    Bing Wei
    Ke Yang
    Jiuzhou Zhao
    Yuxi Chang
    Zihui Ma
    Bing Dong
    Yongjun Guo
    Jie Ma
    Journal of Experimental & Clinical Cancer Research, 33
  • [25] Lower Risk of Hypercoagulability in Non-Small Cell Lung Cancer Patients with EGFR Mutations
    Ohara, S.
    Suda, K.
    Takemoto, T.
    Nishino, M.
    Chiba, M.
    Fujino, T.
    Hamada, A.
    Koga, T.
    Soh, J.
    Misudomi, T.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S653 - S653
  • [26] Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs
    Brueckl, Wolfgang
    Tufman, Amanda
    Huber, Rudolf Maria
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (02) : 143 - 155
  • [27] Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations
    Zwitter, Matjaz
    Rajer, Mirjana
    Stanic, Karmen
    Vrankar, Martina
    Doma, Andrej
    Cuderman, Anka
    Grmek, Marko
    Kern, Izidor
    Kovac, Viljem
    CANCER BIOLOGY & THERAPY, 2016, 17 (08) : 833 - 839
  • [28] Tissue or blood: which is more suitable for detection of EGFR mutations in non-small cell lung cancer?
    Rong Biaoxue
    Yang Shuanying
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2018, 33 (01) : 40 - 48
  • [29] Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)
    Paulina Bracht, Jillian Wilhelmina
    Karachaliou, Niki
    Berenguer, Jordi
    Pedraz-Valdunciel, Carlos
    Filipska, Martyna
    Codony-Servat, Carles
    Codony-Servat, Jordi
    Rosell, Rafael
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2019, 15 (12): : 2607 - 2614
  • [30] Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)
    Christian Manegold
    Petr Zatloukal
    Kurt Krejcy
    Johannes Blatter
    Investigational New Drugs, 2000, 18 : 29 - 42
12345